natgillin/translations-raw huggingface dataset:
 Tell your doctor or pharmacist if any of the side effects listed gets severe or troublesome, or if you notice any side effects not listed in this leaflet.
 Obvestite svojega zdravnika ali farmacevta, če katerikoli neželeni učinek postane resen ali neprijeten ali če opazite katerikoli neželeni učinek, ki ni omenjen v tem navodilu.
 Tell your doctor or pharmacist if you are taking anticoagulants.
 Povejte svojemu zdravniku ali farmacevtu, če jemljete zdravila proti strjevanju krvi.
 Complete when yellow
Injiciranje je končano, ko je okence rumeno.
 Unlocked
Sproščen
 Complete
 Injiciranje je
 Unlocked
 Sproščen
 Do not move the pre-filled pen during the injection.
 Med injiciranjem ne premikajte napolnjenega injekcijskega peresnika.
 Do not press the red button until the safety guard is fully retracted.
 Ne pritiskajte rdečega gumba, dokler ni varnostna zaščita povsem pomaknjena nazaj.
 Do not try to put the needle cap back onto the pre- filled pen
 Ne poskušajte pokrovčka igle znova natakniti na napolnjeni injekcijski peresnik
 Do not twist the grey needle cap
 Ne upogibajte sivega pokrovčka
Do not twist the grey needle cap
 Ne upogibajte sivega pokrovčka.
 15 (functionally anephric, requiring intermittent haemodialysis)*
< 15 (funkcionalno anefričen, zahteva intermitentno hemodializo)
1/10), uncommon (1/1000 to 1/100), rare (1/10,000 to <1/1000) and not known (frequency cannot be estimated from the available data).
< 1/10), občasni ( 1/1.000 do < 1/100), redki ( 1/10.000 do < 1/1.000), neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov).
1/100), rare (1/10,000 to 1/1,000), very rare (1/10,000) and not known (cannot be estimated from the available data).
<1/100); redki (1/10.000 do <1/1.000); zelo redki (<1/10.000) in neznani (iz razpoložljivih podatkov jih ni možno oceniti).
1/1000); and very rare (1/10,000), not known (cannot be estimated from the available data).
< 1/1.000) zelo redki (< 1/10.000) in neznana (ni mogoče oceniti iz razpoložljivih podatkov).
200 mg/day are not recommended.
flukonazola nad 200 mg na dan ne
 MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE
IZDELOVALEC (IZDELOVALCI) BIOLOŠKE ZDRAVILNE UČINKOVINE (UČINKOVIN) IN IZDELOVALEC (IZDELOVALCI), ODGOVOREN (ODGOVORNI) ZA SPROŠČANJE SERIJ
if "0", injection complete
Če je "0", je injiciranje končano
if not "0", need second injection Inject this amount ..........using new pen
Če ni "0", potrebujete drugo injekcijo Injicirajte to količino ..........z novim injekcijskim peresnikom
 Significantly associated with Betaferon treatment for patients with first event suggestive of MS, p < 0.05
 pomembno povezano z zdravljenjem z zdravilom Betaferon pri bolnikih s prvim kliničnim dogodkom, ki kaže na MS, p < 0,05
 Significantly associated with Extavia treatment for patients with first event suggestive of MS, p
 pomembno povezano z zdravljenjem z zdravilom Extavia pri bolnikih s prvim dogodkom, ki kaže na MS, p<0,05
95% CI
[95 % IZ]
95% CI
95% IZ
<0; 82.2
IZ: -386,2; 99,6).
-(2-[1,2-distearoyl-sn-glycero(3)phosphooxy]ethylcarbamoyl)--methoxypoly(oxyethylen)-40 sodium salt (MPEG-DSPE)
α-(2-[1,2-distearoil-sn-glicero(3)fosfooksi]etilkarbamoil)-ω-metoksipoli(oksietilen)-40 natrijeva sol (MPEG-DSPE)
1-Adrenoreceptor Antagonist
ntagonist adrenergičnih receptorjev α1
 haemolytic
 hemolitični
 half-life of clofarabine
-razpolovni čas klofarabina
-glucosidase which is lacking or not active enough in patients with Gaucher disease.
-glukozidaza, ki pri bolnikih z Gaucherjevo boleznijo manjka ali pa ni dovolj aktiven.
2-microglobulin levels at baseline, all efficacy parameters (time to progression and overall survival, as well as response rate) were significantly improved on the bortezomib arm.
Neglede na koncentracijo 2- mikroglobulina ob začetku zdravljenja, so se tudi vsi parametri učinkovitosti (čas do napredovanja bolezni in celokupno preživetje, kot tudi odziv na zdravljenje) v delu preskušanja z bortezomibom statistično značilno izboljšali.
2-microglobulin levels at baseline, all efficacy parameters (time to progression and overall survival, as well as response rate) were significantly improved on the VELCADE arm.
Neglede na koncentracijo 2- mikroglobulina ob začetku zdravljenja, so se tudi vsi parametri učinkovitosti (čas do napredovanja bolezni in celokupno preživetje, kot tudi odziv na zdravljenje) v delu preskušanja z zdravilom VELCADE statistično značilno izboljšali.
 13C:- Difference in parts per thousand (‰) with respect to an accepted international standard.
13C :- Razlika v delih na tisoč (‰) glede na dopustni mednarodni standard.
 As per the judgment of the investigator.
 Po mnenju preiskovalca.
 Needle shield
① Ščitnik igle
 Plunger
② Bat
 Finger-grip
③ Držalo za prste
 Security sleeve
④ Varnostni tulec
This medicine is subject to additional monitoring.
Za to zdravilo se izvaja dodatno spremljanje varnosti.
 After completing all steps in “Step A: Getting ready for an injection”, pull off the blue cap
 Ko ste naredili vse korake v "Korak A: Priprava za injiciranje", snemite modri pokrovček
 Insert the needle into the fold of skin with a quick dart-like motion.
 S hitrim gibom, kot bi vrgli puščico, zabodite iglo v kožno gubo.
 Let the pen warm up at room temperature for 30 to 40 minutes.
 Peresnik za 30 do 40 minut pustite na sobni temperaturi, da se ogreje.
 Prepare the injection site.
 Pripr3a0v-4i0te mesto za injiciranje.
 Keep holding the pen against your skin after releasing the button
 Potem, ko gumb izpustite, peresnik še naprej držite ob koži.
 Throw away syringe and cap
 Brizgo in pokrovček zavrzite
Throw away pen and cap
Peresnik in pokrovček zavrzite
 95 % CI for HR
95% IZ za RT
 95 % CI for median
95% IZ za mediano
 HR (95 % CI)
RT (95% IZ)
 HR (95 % CI)
 RT (95 % IZ)
 Response rate (%) (95 % CI)
Stopnja odzivnosti (%) (95% IZ)
 Stable disease (%)
9,1 (5,9 – 13,2)
EMEA 2007 Page 2/2
EMEA 2007 Stran 2/2
EMEA 2007 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged
EMEA 2007 Reprodukcija in/ali distribucija tega dokumenta je odobrena za nekomercialne namene, dokler je EMEA priznana kot avtor dokumenta.
EMEA 2007 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged
EMEA 2007 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged posebnih skenirnih tehnik, kot je scintigrafija ali računalniška tomografija z emisijo enega fotona – SPECT (single photon emission computed tomography).
EMEA 2007 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged
EMEA 2007 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged psoriazo, ter bolniki, ki so jemali druga zdravila.
EMEA 2007 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged as the local and systemic reactions observed after single, repeated dose and overdose treatment were considered acceptable.
EMEA 2007 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged mesecev, saj so bile reakcije na mestu injiciranja in reakcije telesa, ugotovljene po enkratnem in večkratnem cepljenju ter cepljenju s prevelikim odmerkom, ocenjene kot sprejemljive.
EMEA 2007 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged compared the effects of five days’ treatment with Altargo to those of cefalexin (an oral antibiotic medicine): two studies were carried out in a total of 1,918 patients with infected skin wounds, and the final study was carried out in 545 patients with infected dermatitis (skin inflammation).
V ostalih treh študijah so učinke petdnevnega zdravljenja z zdravilom Altargo primerjali z učinki cefaleksina (peroralnega antibiotika): dve študiji sta bili izvedeni s skupno 1.918 bolniki z okuženimi kožnimi ranami, končna študija pa je bila izvedena s 545 bolniki z infekcijskim dermatitisom (kožnim vnetjem).
EMEA 2007 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged problems) and the rate of deep vein thrombosis (the formation of a blood clot in one of the deep veins of the body, usually in the leg).
EMEA 2007 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged trombotičnih dogodkov (težav, ki jih povzročajo krvni strdki) in pogostost globoke venske tromboze (nastanek krvnega strdka v eni od globokih ven, najpogosteje v nogi).
EMEA 2008 Page 2/2
EMEA 2008 Stran 2/2
EMEA 2008 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged
EMEA 2008 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged hitre rasti kosti, kot so osteoblastne metastaze.
 dexamethasone exposure expected (CYP3A
 pričakovana izpostavljenost deksametazonu (inhibicija CYP3A)
 dexamethasone exposure expected (CYP3A inhibition).
 pričakovana izpostavljenost deksametazonu (inhibicija CYP3A)
 dexamethasone exposure expected (CYP3A inhibition).
 pričakovana izpostavljenost deksametazonu (inhibicija CYP3A).
 Carefully read all the information about hypersensitivity reactions in Section 4 of this leaflet.
 Natančno preberite vse informacije o preobčutljivostnih reakcijah v poglavju 4 tega navodila.
 Don't take a double dose to make up for a missed dose.
 Ne vzemite dvojnega odmerka, če ste pozabili vzeti prejšnji odmerek.
 Don’t drive or operate machinery unless you are sure your alertness has not been affected.
 Ne vozite ali upravljajte strojev, če niste prepričani, da vaša zbranost ni bila prizadeta.
 Don’t drive or operate machinery unless you are sure you’re not affected.
 Ne vozite ali upravljajte strojev, če niste prepričani, da zdravilo na vas tako ne vpliva.
 Don’t drive or operate machinery unless you’re feeling well.
Ne vozite vozil in ne upravljate s stroji, če se ne počutite dobro.
 If you think any of these apply to you, tell your doctor.
 Če menite, da kar koli od navedenega velja za vas, povejte svojemu zdravniku.
 If you think any of these apply to you, tell your doctor.
 Če menite, da kar koli od navedenega velja za vas, se posvetujte z zdravnikom.
 Keep in touch with your doctor, and don’t stop taking Telzir without your doctor’s advice.
 Bodite v stiku s svojim zdravnikom in brez zdravnikovega nasveta zdravila Telzir ne nehajte jemati.
 Read the information ‘Other possible side effects’ in Section 4 of this leaflet.
 Preberite podpoglavje "Drugi možni neželeni učinki" v poglavju 4 tega navodila.
 See a doctor straight away.
 Nemudoma obiščite zdravnika.
 Talk to your doctor about the risks and benefits of taking Tivicay.
 Posvetujte se z zdravnikom o tveganjih in koristih jemanja zdravila Tivicay.
 Talk to your doctor about the risks and benefits of taking Triumeq.
 Posvetujte se z zdravnikom o tveganjih in koristih jemanja zdravila Triumeq.
 Talk to your doctor for further advice on taking acid-lowering medicines with Tivicay.
 Posvetujte se z zdravnikom o jemanju zdravil za zmanjševanje kisline skupaj z zdravilom Tivicay.
 Talk to your doctor for further advice on taking antacid medicines with Triumeq.
 Posvetujte se z zdravnikom o jemanju antacidov skupaj z zdravilom Triumeq.
 Talk to your doctor for further advice on taking calcium supplements, iron supplements or multivitamins with Tivicay.
 Posvetujte se z zdravnikom o jemanju kalcijevih dodatkov, železovih dodatkov ali multivitaminskih pripravkov skupaj z zdravilom Tivicay.
 Talk to your doctor if any of these apply to you before using Triumeq.
 Pred začetkom jemanja zdravila Triumeq se posvetujte s svojim zdravnikom, če kaj od tega velja za vas.
 Talk to your doctor immediately.
 Nemudoma se posvetujte z zdravnikom.
 Talk to your doctor or nurse.
 se posvetujte z zdravnikom ali medicinsko sestro.
 Talk to your doctor.
 se posvetujte z zdravnikom.
 Tell your doctor if any of these applies to you.
Če se karkoli od navedenega nanaša na vas, o tem obvestite svojega zdravnika.
 Tell your doctor if any of these applies to you.
→ Če se karkoli od navedenega nanaša na vas, o tem obvestite svojega zdravnika.
 Tell your doctor if you have heart problems, if you smoke, or have other illnesses that may increase your risk of heart disease such as high blood pressure or diabetes.
 Posvetujte se z zdravnikom, če imate težave s srcem, če kadite ali če imate druge bolezni, ki lahko povečajo tveganje za nastanek bolezni srca, npr. visok krvni tlak ali sladkorno bolezen.
 Tell your doctor if you think any of these applies to you.
Če menite, da se karkoli od navedenega nanaša na vas, o tem obvestite svojega zdravnika.
 Tell your doctor if you think any of these applies to you.
→ Če menite, da se karkoli od navedenega nanaša na vas, o tem obvestite svojega zdravnika.
 Tell your doctor immediately.
 se takoj posvetujte z zdravnikom.
 Tell your doctor immediately.
 Takoj obvestite svojega zdravnika.
 Tell your doctor or pharmacist if any of the side effects gets severe or troublesome, or if you notice any side effects not listed in this leaflet.
Če katerikoli neželeni učinek postane resen ali nadležen, ali če opazite katerikoli neželeni učinek, ki ni omenjen v tem navodilu, obvestite svojega zdravnika ali farmacevta.
 Tell your doctor or pharmacist if you are taking any of these.
 Obvestite zdravnika ali farmacevta, če jemljete kar koli od navedenega.
 Tell your doctor.
 se posvetujte s svojim zdravnikom.
 Tell your doctor.
 se posvetujte z zdravnikom.
 Use an alternative non-hormonal type of contraception such as a condom.
 Uporabljajte alternativno, nehormonsko obliko kontracepcije, kot je kondom.
Ask your doctor or pharmacist for advice before taking this medicine.
Posvetujte se s svojim zdravnikom ali s farmacevtom o tveganjih in koristih zdravljenja z zdravilom Telzir.
Contact your doctor or pharmacist immediately for advice.
Nemudoma se posvetujte z zdravnikom ali s farmacevtom.
Talk to your doctor for further advice on taking calcium supplements, iron supplements or multivitamins with Triumeq.
 Posvetujte se z zdravnikom o jemanju kalcijevih dodatkov, železovih dodatkov in multivitaminskih pripravkov skupaj z zdravilom Triumeq.
Talk to your doctor immediately.
Nemudoma se posvetujte s svojim zdravnikom.
Talk to your doctor immediately.
Nemudoma se posvetujte z zdravnikom.
Talk to your doctor.
Posvetujte se s svojim zdravnikom.
Tell your doctor if any of these applies to you.
Če se karkoli od navedenega nanaša na vas, o tem obvestite svojega zdravnika.
Tell your doctor if any of these apply to you.
 Če se karkoli od navedenega nanaša na vas, o tem obvestite svojega zdravnika.
Tell your doctor if you think any of these could apply to you.
→ Če menite, da se karkoli od navedenega nanaša na vas, o tem obvestite svojega zdravnika.
Tell your doctor immediately.
Nemudoma obvestite svojega zdravnika.
Tell your doctor.
Obvestite svojega zdravnika.
 telaprevir
↓ telaprevirja
 Metformin (with or without sulphonylurea)
 metformin (s sulfonilsečnino ali brez nje)
15 kV air
15 kV zrak
8 kV air
8 kV zrak
 0.5 and < 1.5 x 109/l
 0,5 in < 1,5 x 109/l
 10 and < 100 x 109/l
 10 in < 100 x 109/l
 100 x 109/l, and the haemoglobin level is  9 g/dl (after transfusion if necessary).
≥ 100 x 109/l in koncentracija hemoglobina ≥ 90 g/l (po transfuziji, če je potrebna).
 100 x 109/l, and the haemoglobin level is  9 g/dl (after transfusion if necessary).
 100 x 109/l in koncentracija hemoglobina  90 g/l (po transfuziji, če je potrebna).
 100 x 109/l, and the haemoglobin level is  9 g/dl (after transfusion if necessary).
 100 x 109/l, vrednost hemoglobina pa  9 g/dl (po transfuziji, če je le-ta potrebna).
 106.8 FAID50
 10 6.8 FAID50
 18 years old N=18
 18 let starosti n=18
 2 g/dL decrease in haemoglobin during any
 2 g/dl znižanje hemoglobina v katerem koli
 2 g/dl decrease in haemoglobin during any four week period during treatment (permanent dose reduction)
zmanjšanje vrednosti hemoglobina za  2 g/dl v kateremkoli štiritedenskem obdobju med zdravljenjem (stalno zmanjšanje odmerka)
 30 - < 50 mL/min) renal impairment, the pharmacokinetics of a single 200 mg dose of avanafil were not altered.
< 50 ml/min) okvaro ledvic se farmakokinetika enkratnega odmerka 200 mg avanafila ni spremenila.
 30 IU/ml
tetanusa  30 i.e./ml
 4 mutations from score
 4 mutacije iz rezultata
 5.5 log2 Agglutination titre2 Inactivated Bordetella bronchiseptica cells
 5.5 log2 aglutin. titra2 Inaktivirane celice Bordetelle bronchiseptice
 5.5 log2 Agglutination titre2 Inactivated Bordetella bronchiseptica cells
 5.5 log2 aglutin.titra2 Inaktivirane celice Bordetelle bronchiseptice
 50,000/µl to  150,000/µl
 50.000/µl do  150.000/µl
 6.2 log2 TN titre1 protein dO (non-toxic deletion derivative of Pasteurella multocida dermonecrotic toxin)
 6.2 log2 toksin nevtralizira- jočega titra1 proteina dO (netoksični delecijski derivat dermonekrotičnega toksina Pasteurelle multocide)
 70 years of age.
 70 let.
 F3 liver fibrosis
fibroza jeter  F3
 Grade 2 PN
≥ stopnja 2 PN
 Grade 2 PN
 stopnja 2 PN
 Grade 3 PN
≥ stopnja 3 PN
 Grade 3 PN
 stopnja 3 PN
 PASI 75
PASI  75
 PASI 75a
PASI  75a
1,500 mg daily
1.500 mg na dan
1,500 mg daily
 1.500 mg na dan
1,500 mg daily
 1.500 mg na dan + glimepirid
1,500 mg daily + Glimepiride 4 mg daily
 1.500 mg na dan + glimepirid 4 mg na dan
1,500 mg daily)
 1.500 mg na dan)
1/1,000 to <1/100, rare 1/10,000 to <1/1,000, very rare <1/10,000)) of Extavia use.
1/10.000 do <1/1.000, zelo redki <1/10.000)).
1/1,000 to <1/100; rare: 1/10,000 to <1/1,000; very rare: <1/10,000), not known (cannot be estimated from the available data).
≥ 1/1.000 do < 1/100; redki: ≥ 1/10.000 do < 1/1.000; zelo redki: < 1/10.000), neznana (ni mogoče oceniti iz razpoložljivih podatkov).
1/1,000 to <1/100; rare: 1/10,000 to <1/1,000; very rare: <1/10,000), not known (cannot be estimated from the available data).
≥ 1/1.000 do < 1/100; redki: ≥ 1/10.000 do, < 1/1.000; zelo redki: < 1/10.000), neznana (ni mogoče oceniti iz razpoložljivih podatkov).
1/100 to < 1/10; uncommon:  1/1,000 to ≤ 1/100; rare:  1/10,000 to ≤1/1,000; very rare ≤1/10,000) and system organ class by decreasing order of seriousness; these adverse reactions should be interpreted within the surgical and medical context.
 1/10; pogosti  1/100 do < 1/10; občasni  1/1.000 do < 1/100; redki  1/10.000 do < 1/1.000; zelo redki ≤ 1/10.000) in organski sistem v padajočem vrstnem redu po resnosti; te neželene učinke moramo interpretirati v povezavi s kirurškim in internističnim posegom.
1/100 to <1/10 of patients treated with mycophenolate mofetil in the controlled clinical trials of renal (2°g data), cardiac and hepatic transplant patients are listed in the following table.
1/100 do <1/10 bolnikov, zdravljenih z mofetilmikofenolatom v nadziranih kliničnih preskušanjih bolnikov z ledvičnim (podatki za 2 g), srčnim ali jetrnim presadkom, so našteti v spodnji preglednici.
100,000 c/ml
 100.000 kopij/ml
2log10 decline in HCV RNA
 2 log10 znižanje HCV RNA
3 mmol/l or 12 mg/dl) 4 mg will be an adequate single dosage.
 12 mg/dl) zadošča enkratni odmerek 4 mg.
30 mg daily (+/- Metformin
 30 mg na dan (+/- metformin
4-point reduction in the SELENA-SLEDAI score, and no new British Isles Lupus Assessment Group (BILAG) A organ domain score or 2 new BILAG B organ domain scores, and no worsening (>0.30 point increase) in Physician’s Global Assessment score (PGA)
zmanjšanje rezultata SELENA-SLEDAI za  4 točke in brez novih točk organskega področja BILAG (British Isles Lupus Assessment Group) A ali 2 novi točki organskega področja BILAG B ter brez poslabšanja (povečanja za > 0,30 točke) rezultata PGA (Physician's Global Assessment)
5.5 log2 Aggl. titre inactivated B. bronchiseptica cells dl-α-tocopherol acetate
 5,5 log2 aglutinacijskega titra1 inaktiviranih celic bakterije Bordetella bronchiseptica dl-alfa-tokoferol acetata
50% improvement
 50 % izboljšanje
500 cells/L
mepolizumab
6.2 log2 TN titre Protein dO
 6,2 log2 toksin nevtralizirajočega titra1 proteina dO
6.2 log2 TN titre Protein dO (non-toxic deletion derivative of Pasteurella multocida dermonecrotic toxin)
 6,2 log2 toksin nevtralizirajočega titra1 proteina dO (netoksični delecijski derivat dermonekrotičnega toksina Pasteurella multocida)
8 (95%CI)
 8 (95 % IZ)
PASI 75
PASI  75
PASI 75a
PASI  75a
 Do not move the pre-filled pen during the injection.
 Napolnjenega injekcijskega peresnika med injiciranjem ne smete premikati.
 Do not press the red button until the safety guard is fully retracted.
 Ne pritiskajte rdečega gumba, dokler ni varnostna zaščita povsem pomaknjena nazaj.
 Do not try to put the needle cap back onto the pre-filled pen
 Ne poskušajte pokrovčka igle znova natakniti na napolnjeni injekcijski peresnik
 Do not twist the grey needle cap
 Ne upogibajte sivega pokrovčka.
 Unfold and lay flat 
 Razgrnite in položite na ravno podlago
 Bad headache with nausea, vomiting, stiff neck, fever, and sensitivity to light could be signs of AMS.
 Hud glavobol s siljenjem na bruhanje, bruhanje, tog vrat, zvišana telesna temperature in občutljivost na svetlobo so lahko znaki AMS.
 Call your doctor.
 se posvetujte z zdravnikom.
 Check with your doctor if you think any of these may apply to you.
 Posvetujte se z zdravnikom, če menite, da kaj od tega velja za vas.
 Check with your doctor if you think any of these may apply to you.
 Če menite, da kaj od tega velja za vas, se posvetujte z zdravnikom.
 Check with your doctor if you think this applies to you.
 Če menite, da se zgornja navedba nanaša na vas, se posvetujte z zdravnikom.
 Check with your doctor if you think this applies to you.
 Posvetujte se s svojim zdravnikom, če mislite, da to velja za vas.
 Check with your doctor if you think this applies to you.
 Posvetujte se z zdravnikom, če mislite, da to velja za vas.
 Check with your doctor if you think this applies to you.
 Če menite, da to velja za vas, se posvetujte z zdravnikom.
 Check with your doctor if you think this may apply to you.
 Posvetujte se z zdravnikom, če menite, da kaj od tega velja za vas.
 Contact a doctor immediately if you get these symptoms.
→ Če se vam pojavijo ti simptomi, se nemudoma posvetujte z zdravnikom.
 Contact a doctor immediately if you get these symptoms.
 Nemudoma se posvetujte z zdravnikom, če se vam pojavijo ti simptomi.
 Contact a doctor immediately if you get these symptoms.
 Če se vam pojavijo ti simptomi, nemudoma obvestite zdravnika.
 Contact a doctor immediately.
 Nemudoma obvestite zdravnika.
 Contact your doctor if you experience the following signs and symptoms: severe headache, neck stiffness, drowsiness, fever, photophobia, nausea, and vomiting after receiving Hizentra.
 Takoj se posvetujte z zdravnikom, če po uporabi zdravila Hizentra opazite naslednje znake ali simptome: hud glavobol, tog vrat, dremavost, zvišala telesna temperatura, fotofobija, siljenje na bruhanje in bruhanje.
 difficulty swallowing or breathingContact a doctor immediately if you get these symptoms.
 Nemudoma se posvetujte z zdravnikom, če se vam pojavijo ti simptomi.
 Do not take a double dose to make up for a forgotten dose.
 Ne vzemite dvojnega odmerka, če ste pozabili vzeti prejšnji odmerek.
 Don’t drive or use machines unless you are sure you’re not affected.
 Ne upravljajte z vozili ali stroji, če se ne počutite dobro.
 Don’t drive or use machines unless you are sure you’re not affected.
 Ne vozite ali upravljajte s stroji, razen, če ste prepričani, da vaša sposobnost ni prizadeta.